BRTX - Company ID 0001505497
The table below shows BioRestorative Therapies, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.81M | -$2.78M | -$2.32M | -$2.38M | -$1.59M | -$813.70K |
| Capital expenditure | - | $36.40K | - | $60.02K | $109.57K | - |
| Investing cash flow | $968.45K | $2.37M | -$4.93M | $2.54M | -$109.57K | - |
| Dividends paid | - | - | - | - |
BioRestorative Therapies, Inc. reported operating cash flow of -$10.79M for fiscal year 2025. That is down 31.1% from -$8.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.67M (FY 2013) to -$10.79M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | $0.00 | - | - | - | - | - |
| Financing cash flow | $4.44M | $1.09M | $7.52M | - | - | $250.00K |